Encell EN001 Receives US FDA Orphan Drug Designation for Duchenne Muscular Dystrophy

Encell, a company specializing in cell and gene therapies (CGT), announced on the 6th that its allogeneic umbilical cord-derived mesenchymal stem cell therapy candidate EN001 has additionally received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for Duchenne muscular dystrophy (DMD) as an indication.

This is the second achievement following its previous ODD approval for Charcot-Marie-Tooth disease (CMT). As a result, EN001 has been recognized for its therapeutic potential in rare diseases across two distinct pathological areas: peripheral neuropathy (CMT) and muscle degenerative disease (DMD). For drugs designated as ODD, the FDA supports the development and commercialization of innovative new medicines by offering various incentives, including seven years of market exclusivity after marketing approval, tax credits for clinical trial costs, and priority review.

원본보기 아이콘

DMD is a pediatric rare disease caused by defects in the dystrophin gene, which encodes a protein essential for maintaining muscle cells. Due to progressive muscle weakness, most patients lose their ability to walk after their teenage years, and currently there are very few treatment options that fundamentally slow the progression of the disease.

EN001 is a therapeutic agent based on allogeneic umbilical cord-derived mesenchymal stem cells (WJ-MSCs). It incorporates Encell's proprietary cell culture platform technology, ENCT, which suppresses cellular aging and enhances the secretion of factors related to anti-inflammation and tissue regeneration. It is considered to have therapeutic potential not only for the recovery of peripheral nerve damage, but also for controlling inflammation and preserving function in muscle tissue.

Encell CEO Jang Jongwook said, "This additional ODD designation is an objective validation that EN001 is a platform technology applicable not only to a single disease but across a broad range of intractable rare diseases with high unmet medical needs," adding, "We will focus our capabilities on accelerating clinical development and generating tangible global business outcomes going forward."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.